Business
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first passive monitoring tool for psychiatric conditions.Pooled analysis of three prospective observational studies demonstrated 90% within-person concordance between EMOCARE scores and clinician-rated MADRS (r = 0.895; p = 0.016).EMOCARE also achieved strong sensitivity to symptom change against PHQ-9 (ρ
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"image","alt":"NRx Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"NRx Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/4ef53875d129fcc14f2614dd5795d5a9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oQlnKXAw77IR4.RQxkfHUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/4ef53875d129fcc14f2614dd5795d5a9","width":300,"height":300},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/oQlnKXAw77IR4.RQxkfHUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/4ef53875d129fcc14f2614dd5795d5a9","width":300,"height":300}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first passive monitoring tool for psychiatric conditions.","length":251,"tagName":"p"}]},{"val":[{"type":"text","content":"Pooled analysis of three prospective observational studies demonstrated 90% within-person concordance between EMOCARE scores and clinician-rated MADRS (r = 0.895; p = 0.016).","length":174,"tagName":"p"}]},{"val":[{"type":"text","content":"EMOCARE also achieved strong sensitivity to symptom change against PHQ-9 (ρ = 0.834; p < 0.001) on consecutive-visit measurements.","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"The validated technology is being deployed across the Hope Therapeutics interventional psychiatry network as a patient-facing self-monitoring and safety-net tool.","length":162,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":720,"olType":false},{"type":"text","content":"SARASOTA, Fla. and PARIS, May 28, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) today announced that its strategic partner, Emobot Health, presented a late-breaking poster at the 2026 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), reporting the first pooled clinical validation of EMOCARE, the investigational passive, multimodal, smartphone-based “Depression Thermometer” that powers the Emobot app now being deployed across the Hope Therapeutics network of interventional psychiatry cl...